Contents

Section 1: Peritoneal Disease

1. **Pathophysiology of Peritoneal Malignancies and Modalities of Treatment 3**
   Sarah McPartland, Martin D. Goodman
   - The Peritoneal Cavity 3
   - Malignancies of the Peritoneal Cavity 5
   - Tumor Biology of Peritoneal Malignancies 7
   - Treatment of Peritoneal Malignancies 8

2. **Pseudomyxoma Peritonei and Peritoneal Mucinous Carcinoma of Appendiceal Origin 18**
   Paul H. Sugarbaker
   - The Primary Appendiceal Neoplasm 18
   - Peritoneal Dissemination of Mucinous Appendiceal Neoplasms 22
   - Outcomes of the Treatment at the Washington Cancer Institute of Using Quantitative Prognostic Indicators 25

3. **Carcinomatosis from Colon Cancer 33**
   Terence C. Chua, Jesus Esquivel
   - Natural History of Carcinomatosis 33
   - Systemic Chemotherapy for Colorectal Carcinomatosis 34
   - Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Treatment for Colorectal Carcinomatosis 36
   - Limitations of General Acceptance of Hyperthermic Intraperitoneal Chemotherapy for Carcinomatosis from Colorectal Cancer 39
   - Future Directions 40

4. **Malignant Peritoneal Mesothelioma (MPM) 43**
   Haroon A. Choudry, David L. Bartlett
   - Background and Epidemiology 43
   - Etiology and Pathogenesis 43
   - Clinical Presentation 44
   - Diagnosis 45
   - Treatment 47
   - Consensus Statement: Management Algorithm for MPM 55

Section 2: Gynecological Malignancies

5. **Intraperitoneal Chemotherapy for Ovarian Cancer 61**
   Anne Garrison, Sarah H. Hughes
   - Theory 62
   - First-Line Treatment 63
   - Current Practice Standards 65

6. **Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer 67**
   C. William Helm
   - Current Standard Treatment for Advanced Ovarian Carcinoma 68
   - Rationale of HIPEC and IP Therapy 68
   - Time-Points for Treatment of EOC 69

- Definitions of Platinum Response 69
- Front-Line Treatment of EOC 69
- Interval Debulking 71
- Recurrent Disease 73
- The Problem of Front-Line Failure 75
- Surgical Considerations 76

Section 3: Melanoma, Sarcoma and Lung

7. Isolated Limb Perfusion (ILP) and Isolated Limb Infusion (ILI) for Locally Advanced Malignant Melanoma 83

Giorgos C. Karakousis, Douglas L. Fraker

- Background: In-Transit Melanoma 83
- History and Technique of ILP 84
- Efficacy of ILP 85
- Clinical and Pathologic Factors Predicting Response after ILP 86
- Safety and Toxicity 86
- Isolated Limb Infusion 87

8. Isolated Limb Perfusion for Extremity Sarcoma 91

Tim Pencavel, Andrew Hayes

- History of Isolated Limb Perfusion 91
- Technical Aspects of Isolated Limb Perfusion 92
- Isolated Limb Perfusion in Clinical Practice for Sarcoma 95
- Response Rates to Isolated Limb Perfusion for Sarcoma 98
- Side Effects and Tolerability 99
- Treatment after Isolated Limb Perfusion 100
- Isolated Limb Infusion 101
- Future Approaches for Isolated Limb Perfusion 101

9. Hyperthermic Intrathoracic Chemotherapy 105

Neil A. Christie, Daniel C. Wiener

- Malignant Pleural Mesothelioma 105
- Thymic Neoplasms 110
- Lung Carcinoma 111

10. Thermal Ablation of Lung Tumors and Pulmonary Metastases 113

Chaitan K. Narsule, Benedict D.T. Daly, Hiran C. Fernando

- Radiofrequency Ablation 113
- Microwave Ablation 115
- Ablation Technique 116
- Complications of Lung Ablation 119

Section 4: Liver

11. Hepatic Arterial Infusion Pumps 123

Andrea Cercek, Nancy E. Kemeny

- Hepatic Arterial Infusion Pump Placement 123
- Hepatic Arterial Infusion Catheter Related Complications 124
- Pharmacological Principles for Drug Selection 124
- 5-Fluoro-2-Deoxyuridine 125
- HAI-FUDR Toxicities and Management 125

- Trials Evaluating HAI-FUDR in Unresectable Metastatic CRC 126
- HAI in Combination with Systemic Chemotherapy in Unresectable Metastatic CRC 127
- Adjuvant HAI following Liver Resection 128
- HAI for Primary Liver Cancer 129

12. Hepatic Arterial Therapies for Colorectal Liver Metastases....132

Hebat Allah Mohamed Saad El-Din Fouad, Robert C.G. Martin II

- Hepatic Arterial Infusion Chemotherapy 132
- Transarterial Chemoembolization 133
- Drug-Eluting Beads 134

13. Ablations RFA vs Microwave vs Other....141

Lisa Rutstein, Abby Crume

- Radiofrequency Ablation 141
- Microwave Ablation 143

14. Isolated Hepatic Perfusion with TNF and Melphalan for Patients with Diffuse Hepatic Metastases....146

Susan B. Kesmodel, H. Richard Alexander Jr

- Development of IHP and Initial Clinical Results 147
- Open Technique for IHP 148
- Isolated Hepatic Perfusion for CRC Liver Metastases 149
- Isolated Hepatic Perfusion for Ocular Melanoma 152
- Isolated Hepatic Perfusion for Neuroendocrine Tumors 153
- Percutaneous Hepatic Perfusion 153

Index....159